The Technical Analyst
Select Language :
Catalyst Biosciences Inc [CBIO]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Catalyst Biosciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Catalyst Biosciences Inc is listed at the  Exchange

-2.65% $0.511

America/New_York / 30 okt 2023 @ 16:00


Catalyst Biosciences Inc: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 19.42 mill
EPS: -20.70
P/E: -0.0247
Earnings Date: Oct 25, 2023
SharesOutstanding: 37.98 mill
Avg Daily Volume: 0.437 mill
RATING 2023-10-30
B
Neutral
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Sell
P/E: Sell
Price To Book: Strong Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenuen/an/an/an/an/a
Gr.Profitn/an/a
Ebitn/a
Asset
Debtn/an/an/a
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -0.0247 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
0.00x
Company: PE -0.0247 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 7.63 - 7.71

( +/- 0.48%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2023-11-20 Luo Ying Buy 3 350 897 Stock Option (Right to Buy)
2023-10-30 Luo Ying Buy 2 840 376 Common Stock
2023-11-20 Luo Ying Buy 2 262 755 Stock Option (Right to Buy)
2023-11-20 Ye Weiguo Buy 1 665 115 Stock Option (Right to Buy)
2023-11-20 Ma Songjiang Buy 4 510 047 Stock Option (Right to Buy)
INSIDER POWER
21.61
Last 85 transactions
Buy: 88 748 347 | Sell: 111 334 812

Forecast: 01:40 - $0.818

Live Trading Signals (every 1 min)

SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $0.511 (-2.65% )
Volume 0.461 mill
Avg. Vol. 0.437 mill
% of Avg. Vol 105.36 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Catalyst Biosciences Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Catalyst Biosciences Inc

RSI

Intraday RSI14 chart for Catalyst Biosciences Inc

Last 10 Buy & Sell Signals For CBIO

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Catalyst Biosciences Inc

CBIO

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.

Last 10 Buy Signals

Date Signal @
SQQQMar 28 - 14:57$10.41
FTNUSDMar 28 - 14:561.810
^NYAMar 28 - 14:42PTS18 301
^SPXMar 28 - 14:425 250.40
TUSDUSDMar 28 - 14:55$0.996
KP3RUSDMar 28 - 14:5495.68
APE18876USDMar 28 - 14:542.01
ANKRETHUSDMar 28 - 14:554 068.09
BUSDUSDMar 28 - 14:550.995
BTCBUSDMar 28 - 14:5570 529

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.